| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$69.9M | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $140.1M | Trading Days | 354 |
| 52W High | 17.94 |
| 52W Low | 3.35 |
| % Off High | −64.21% |
| YTD | −51.09% | 1Y | −52.72% |
| Since incept. (ann.) | −42.44% |
| Ann. Volatility (1Y) | 126.79% | Ann. Volatility (3Y) | 124.45% |
| Sharpe (1Y) | 0.08 | Sharpe (3Y) | 0.21 |
| Max Drawdown (1Y) | −80.01% | Max Drawdown (3Y) | −80.01% |
| Beta (3Y, vs SPY) | 3.91 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ADCT | ADC Therapeutics SA | $141.2M | — |
| CNTN | Canton Strategic Holdings, Inc. | $142.4M | — |
| HURA | TuHURA Biosciences, Inc./NV | $135.6M | — |
| MSLE | Satellos Bioscience Inc. | $146.2M | — |
| EQ | Equillium, Inc. | $146.7M | — |
| MIST | Milestone Pharmaceuticals Inc. | $133.2M | — |
| UNCY | Unicycive Therapeutics, Inc. | $131.9M | — |
| GNLX | GENELUX Corp | $130.9M | — |
| PMN | ProMIS Neurosciences Inc. | $130.2M | — |
| KRRO | Korro Bio, Inc. | $151.4M | — |
| NGEN | NERVGEN PHARMA CORP. |
| $128.2M |
| — |
| DERM | Journey Medical Corp | $154.6M | — |
